ea0056p861 | Pituitary - Clinical | ECE2018
Fleseriu Maria
, Iweha Chioma
, Salgado Luiz
, Mazzuco Tania Longo
, Patino Heather
, Campigotto Federico
, Maamari Ricardo
, Limumpornpetch Padiporn
Introduction: Pasireotide sc has a proven favourable efficacy and safety profile in CD patients, as shown in clinical trials. Here, we report safety and efficacy results from an expanded-access study designed to allow CD patients to receive pasireotide until regulatory approval for commercial use and reimbursement was obtained in their country.Methods: Pasireotide-naïve adults with CD (mean 24-hour urinary free cortisol [mUFC; of three samples] exce...